Kaplan Fox Alerts Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Possible Securities Law Violations

Fulcrum Therapeutics discontinued its pociredir program for sickle cell disease after FDA concerns that PRC2-targeting drugs carry equivalent malignancy risk, eliminating any viable regulatory path for further development. Shares fell from $6.42 on June 1, 2026 to $3.14 on June 2, 2026 (-51.09%), following the end-of-phase discussions citing an unexpectedly high rate of secondary hematologic malignancies with tazemetostat (Tazverik®). The article also notes an ongoing securities-fraud investigation by Kaplan Fox & Kilsheimer, adding legal overhang for investors.

Analysis

This is now a balance-sheet and financing story more than a science story. Once a lead program is functionally dead, equity value migrates toward residual cash, while the legal investigation adds a second layer of overhang that can slow any attempt to redeploy capital, raise cash, or partner the rest of the pipeline. The real downside risk is not another 50% gap in one session; it is a slow bleed from dilution, reverse-split optics, and lower bargaining power with future counterparties.

The spillover is broader than FULC. Any small-cap platform marketed around the same biological axis should trade with a higher failure discount, and diversified biotech proxies like XBI can see mild sentiment pressure if investors generalize a class-risk narrative. In the near term, that usually hurts the weakest balance sheets first: companies with one-shot pipelines, short cash runways, or pending trial readouts get marked as financing candidates rather than platform stories.

The contrarian point is that after a collapse of this magnitude, downside can become convex only if the cash burn is meaningful or disclosure risk widens. If net cash is close to or above the current equity value, shorting here is a lower-quality trade unless a new dilution event is imminent. The key falsifier is a clean 10-Q/8-K showing a long runway and no need for financing; the key accelerant is any new disclosure suggesting the program failure contaminates the rest of the pipeline or triggers a capital raise within 1-2 quarters.

Key Decisions for Investors

• Sell/short FULC on any 15-25% relief rally over the next 1-3 weeks; use a tight stop above the pre-gap breakdown area, because the easy money from the first repricing is likely already gone.
• If options are liquid, buy 3-6 month FULC put spreads rather than outright puts to express litigation/dilution risk while capping theta bleed; best risk/reward is the next financing window, not same-day news.
• Do not short the biotech beta basket immediately; instead watch XBI/IBB for contagion only if other PRC2 or single-asset names start de-rating. That would create a cleaner sector hedge than forcing one now.
• Set an alert on the next quarterly filing for cash runway and share count. If burn implies <12 months of liquidity, the thesis shifts from event-driven to structural and downside can extend well beyond the current drawdown.